The choice of an antiretroviral regimen can often impact on adherence, treatment satisfaction and therefore influence on clinical outcome. These concerns are particularly true in adolescents. In this setting, adherence is usually affected by multifactor events and biopsychosocial factors, which connect and changeover time. We evaluated the effect of a switch to a single-pill fixed-dose regimen on patient-reported outcomes, virologic and immunologic outcomes, and safety in a cohort of adolescents with perinatal HIV-1 infection. In addition, we evaluated the effect on low-level residual HIV-RNA. An open-label, non-randomised study was performed: 12 adolescents with a confirmed viremia B50 copies/mL treated with lamivudine or emtricitabine, tenofovir and efavirenz were switched to one-pill fixed-dose regimen of emtricitabine/tenofovir/efavirenz. At the end of followup, the new regimen was associated with improvements in treatment satisfaction, HIV-symptoms, whereas adherence remained high. No immunological or virological significative changes were observed. No side-effects were registered. Moreover, the low-level residual HIV-RNA was B3 copie/mL in all patients. One-pill fixed-dose regimen is an added value that favours adherence, reduces HIV-symptoms, improves patients' satisfaction and could better control of HIV-RNA in adolescents, too.
Introduction
Prospective paediatric studies have shown that the risk of virological failure increases when the proportion of missed doses increases (Flynn et al., 2004; Van Dyke et al., 2002; Watson & Farley, 1999) . A major obstacle to the success of therapy in children and adolescents is poor adherence (Murphy et al., 2001; Rudy et al., 2006; Shah et al., 2007) .
Adherence can be affected by multiple events and biopsychosocial factors, which interrelate and changeover time. HIV-infected adolescents face specific adherence challenges (Belzer, Fuchs, Luftman, & Tucker, 1999; Ryan et al., 2008) . In adults, several studies have identified pill burden and lifestyle issues (not carrying medication, change in schedule) as barriers to optimum adherence (Boyle et al., 2008; Flandre et al., 2002; Levi & Drotar, 1998; Maggiolo et al., 2002; Stone, Jordan, Tolson, Miller, & Pilon, 2004; Trotta et al., 2003) , no data are available in children and adolescents. Moreover, in adults, a number of studies have revealed how treatment simplification strategies could enhance patients' adherence to combined antiretroviral treatment (cART) (Boyle et al., 2008; Flandre et al., 2002; Stone et al., 2004; Trotta et al., 2003) . Furthermore, common HIV-related symptoms (e.g., gastro-intestinal, respiratory, neurological, constitutional, allergy and psychological discomfort) are associated with a lower adherence and their associations with worse health outcomes have been reported early in the epidemic (Harding, Molloy, Easterbrook, Frame, Higginson, 2006; Max & Sherer, 2000) . A significant proportion of patients receiving cART experiences such symptoms often requiring drug discontinuation or treatment change.
Consequently, many studies have focused on describing the prevalence of HIV-related symptoms in adults and on identifying effective treatments for these symptoms (Holzemer et al., 1999) . Fewer studies have examined these symptoms and their treatments in children and adolescents.
Little is known about the preferences of adolescents in terms of cART regimens and about factors influencing these choices.
It is also crucial to note that improved HIV-RNA assay technology has made possible the accurate detection of a low-level residual HIV-RNA, allowing *Corresponding author. Email: antonio.dibiagio@hsanmartino.it the quantitation of HIV-RNA below the 50 copies/ mL limit. The source and dynamics of this residual HIV-RNA are currently unknown. Viremia could arise from on-going cycles of viral replication in a sanctuary site where there is suboptimal drug penetration, from long-lived productively infected cells, or from activation of virus expression from latently infected cell reservoirs (Bonora et al., 2009; Palmisano et al., 2005) , however, no data are actually available in children and adolescents who were vertically infected with HIV.
The objectives of the study were to verify, in adolescents perinatally infected with HIV-1, if simplification of cART could influence: (1) adherence rate, (2) prevalence of HIV symptoms and (3) patient's preference and how these parameter could changeover time; further, we analysed the effect of the simplification strategy on low-level residual HIV-RNA.
Methods

Study design
This was a 24-week, open-label and descriptive study in adolescents perinatally infected with HIV-1 who had achieved virologic suppression on their current regimen containing emtricitabine (FTC) or lamivudine (3TC) 'tenofovir (TDF) 'efavirenz (EFV).
Patients were switched to one-pill fixed-dose regimen of FTC/TDF/EFV, then did not change their therapy in terms of active molecules or doses, but simply reduced the daily number of pills in their regimen from three or two to one.
Due to the limits of the sample and to the uncontrolled nature of the study we limited statistical analysis to the descriptive level. Any inference would have been inappropriate due to the low power of the study. The study therefore, may only generate hypothesis for further research.
The study was approved by San Martino Hospital ethics committee. All patients or parents signed a written consent before starting study procedures.
Participants
The San Martino University Teaching and Hospital in Genoa, Italy, provides case management service to 52 children and adolescents born with HIV infection. Patients were selected between December 2008 and June 2009.
To be eligible, patients had to be receiving a stable cART for over six months, have an adequate weight (defined as exceeding 60 kg) and a plasma HIV-1 RNA value B50 copies/mL using the Versant HIV-1 RNA 3.0 assay bDNA (Siemens Medical Solutions Diagnostics, Malvern, PA) at least for six months prior to and at screening.
All 12 eligible patients were enrolled in the study. All patients' related variables were collected at the moment of treatment switch (baseline) and one, three and six months after the switch.
Study visits occurred at baseline, weeks 4, 12 and 24. Laboratory analyses (haematology, serum chemistries, urinalysis and surrogate markers of HIV infection HIV-RNA and CD4 T-cell counts) and physical examinations were performed at all study visits. At the same time, patients were questioned for the occurrence of adverse events.
The low-level residual HIV-RNA was quantified by ultrasensitive assay (detection limit: B3 copies/ mL), Versant TM KPCR Molecular System (Siemens Healthcare Diagnostics).
Treatment adherence
Patient-reported adherence to treatment was assessed using a visual analogue scale (VAS) (Giordano, Guzman, Clark, Charlebois, & Bangsberg, 2004) . Adherence was investigated with four separate questions considering two different recall periods: last month and last week. For each period patients were asked to report the proportion of doses taken and the proportion of doses taken with respect to the daily timing (92 hours). In both cases a VAS scale was used to collect data.
HIV symptom index
Data were collected on a 20-items self-reported questionnaire that address the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment (Justice et al., 2001) . The following symptom categories were addressed: gastrointestinal symptoms (bloating, pain in the stomach, nausea and vomiting, diarrhoea or loose bowel movements); respiratory symptoms (dyspnoea); neurological symptoms (peripheral neuropathy, dizziness, muscle or joint pain); psychological discomfort (change in mood, problems in having sex, changes in sleep pattern, trouble remembering, changes of body appearance); constitutional symptoms (fever, headache, fatigue, loss of appetite, weight loss or wasting); and allergy symptoms (rash, skin and hair problems). Symptoms were analysed individually and collectively.
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Patient's preference and judgement of cART
This aspect has been investigated by a 4-item selfreported questionnaire comparing the new therapy to the previous and relating to tolerability, convenience, simplicity and potency. A value of 50% on the VAS scale indicated indifference, higher values a preference for the one-pill fixed-dose regimen, while lower values were indicative of a preference for the previous cART.
Results
Twelve patients were enrolled and completed the study, no patients stopped therapy due to adverse events. Of these, seven were females. The mean age was 16 years with a range from 12 to 22 years. Eleven patients were Caucasian and one North African. According to the US Centers for Diseases Control and Prevention (CDC) revised classification system for HIV infection in children, one was C, six were A and five were B. Patients had been receiving cART for a mean of 10.9 years (range 3.6Á20.1 years) and had been on their current cART for a mean of 4.1 years (range 1.2Á6 years). Overall, the mean number of cART regimens the patients were exposed to was 4.6 (range 3Á8). At baseline the mean CD4 T-cell count and percentage were 808.7 cells/mL (range 419Á1423) and 34.3% (range 26Á48), respectively. All patients had a HIV-RNA B50 copies/mL and five patients (41%) had a viral load below 3 copies/mL. Moreover, none of the patients had significant alterations of haematological or biochemical profiles and of urine analysis.
After six months, an increase of the median CD4 T-cell count and percentage was observed: 783 cells/ mL (range 0 408Á1474) and 38.1% (range 0 25Á50), respectively, and all patients had a viral load below 3 copies/mL.
Treatment adherence
Adherence to treatment, as measured by the VAS, was already high at baseline being the number of doses taken in the last month and in the last week 96.6% and 99.1%, respectively. Twenty-four weeks after introduction of FTC/TDF/EFV we obtained similar results 98.3% and 99.1%.
HIV symptom index
At baseline, when actively asked for, 11 adolescents reported several symptoms that could be related to the assumption of cART; seven patients (58.3%) reported the presence of trouble remembering, whereas symptoms reported by a significant number of patients (30%) included fatigue and muscles aches.
After 24 weeks, the number of patients that reported any symptoms decreased (9 vs 11) and the number of symptoms each patient-reported decreased, too (29 vs 46). The most common symptoms indicated after six months were: trouble remembering, nausea and vomiting (25%) and muscles aches (16.6%).
Patient's preference and judgement of cART
The comparative evaluation of combined single tablet therapy with that based on the use of two or three tablets once-a-day is in favour of the most compact regimen both in terms of patient's preferences, tolerability, convenience and simplicity. For all considered characteristics (Figure 1) , the one-pill regimen was the preferred choice as early as one month after the change, and the preference for this regimen increased after six months. 
Discussion
In our study, we observed that by replacing a 3TC or FTC, TDF and EFV as combined tablets with onepill fixed-dose adherence rates did not change. However, adherence rates, reported by our adolescent's sample, were higher than that observed in other studies (Murphy et al., 2005; Rudy et al., 2010) . As a matter of fact, in our study, all adolescents were already a once-daily regimen (3TC/FTC 'TDF and EFV) and the introduction of the one-pill fixed-dose just reduced the number of pills. This change can explain the slight improvement of adherence rates we observed.
In the present study, the switch from three or two pills to the one-pill fixed-dose was associated with sustained improvements of several symptoms commonly related to HIV infection or cART. It is also crucial to note that the compact one-pill was well accepted by adolescents that scored it as highly preferable in terms of simplicity, convenience, tolerability and potency. It is probable that the convenience of the one-pill fixed-dose results very charming and this may influence the patients' judgments in terms of potency. The same results were obtained in adults replacing FTC 'TDF 'EFV with a fixeddose combination and thus non-modifying treatment in terms of type and dose of drugs (Airoldi et al., 2010) .
The efficacy of the one-pill fixed-dose was similar to the FTC or 3TC, TDF and EFV separated tablets HAART as measured by means of viral suppression and the gain of CD4 T-cells, as previously reported (Airoldi et al., 2010; DeJesus et al., 2009; Hodder et al., 2010) .
However, it is intriguing that although only marginal, the increment of adherence paralleled, in our study, the virological outcome when measured with an ultrasensitive assay for HIV-RNA. For the first time, at the best of our knowledge, in our study a simplification strategy was evaluated in adolescents, and data on low-level residual HIV-RNA were collected.
Our study had some significant limitations. The small sample and the uncontrolled design did not allow for inferential analysis. An additional drawback is that our results are limited to 24 weeks of observation.
Nevertheless, the strict relationship between adherence and virologic response is highlighted by our results that seem to indicate how more sensitive tests may catch even apparently non-significant variations of adherence.
